文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

NLRC5 通过调节 NF-κB 通路介导的错配修复基因缺陷促进子宫内膜癌进展。

NLRC5 promotes endometrial carcinoma progression by regulating NF-κB pathway-mediated mismatch repair gene deficiency.

机构信息

Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Anhui Medical University, No 678 Furong Road, Hefei, 230022, Anhui, China.

Department of Obstetrics and Gynecology, The Frist Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.

出版信息

Sci Rep. 2024 May 30;14(1):12447. doi: 10.1038/s41598-024-63457-2.


DOI:10.1038/s41598-024-63457-2
PMID:38822039
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11143240/
Abstract

The innate immune molecule NLR family CARD domain-containing 5 (NLRC5) plays a significant role in endometrial carcinoma (EC) immunosurveillance. However, NLRC5 also plays a protumor role in EC cells. Mismatch repair gene deficiency (dMMR) can enable tumors to grow faster and also can exhibit high sensitivity to immune checkpoint inhibitors. In this study, we attempted to determine whether NLRC5-mediated protumor role in EC is via the regulation of dMMR. Our findings revealed that NLRC5 promoted the proliferation, migration, and invasion abilities of EC cells and induced the dMMR status of EC in vivo and in vitro. Furthermore, the mechanism underlying NLRC5 regulated dMMR was also verified. We first found NLRC5 could suppress nuclear factor-kappaB (NF-κB) pathway in EC cells. Then we validated that the positive effect of NLRC5 in dMMR was restricted when NF-κB was activated by lipopolysaccharides in NLRC5-overexpression EC cell lines. In conclusion, our present study confirmed the novel NLRC5/NF-κB/MMR regulatory mechanism of the protumor effect of NLRC5 on EC cells, thereby suggesting that the NLRC5-mediated protumor in EC was depend on the function of MMR.

摘要

天然免疫分子 NLR 家族 CARD 结构域包含 5(NLRC5)在子宫内膜癌(EC)免疫监视中发挥重要作用。然而,NLRC5 在 EC 细胞中也发挥促肿瘤作用。错配修复基因缺陷(dMMR)可使肿瘤生长更快,并对免疫检查点抑制剂表现出高度敏感性。在这项研究中,我们试图确定 NLRC5 是否通过调节 dMMR 介导 EC 的促肿瘤作用。我们的研究结果表明,NLRC5 促进了 EC 细胞的增殖、迁移和侵袭能力,并在体内和体外诱导了 EC 的 dMMR 状态。此外,还验证了 NLRC5 调节 dMMR 的机制。我们首先发现 NLRC5 可以抑制 EC 细胞中的核因子-κB(NF-κB)通路。然后我们验证了当 NLRC5 过表达的 EC 细胞系中 NF-κB 被脂多糖激活时,NLRC5 在 dMMR 中的正效应受到限制。总之,本研究证实了 NLRC5/NF-κB/MMR 调节机制在 NLRC5 对 EC 细胞促肿瘤作用中的新作用,从而提示 NLRC5 介导的 EC 促肿瘤作用依赖于 MMR 的功能。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e2d/11143240/e1da7fe8f2a0/41598_2024_63457_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e2d/11143240/118721c42b85/41598_2024_63457_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e2d/11143240/683ee3ab13a9/41598_2024_63457_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e2d/11143240/87a243761c0f/41598_2024_63457_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e2d/11143240/616402925d73/41598_2024_63457_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e2d/11143240/320ac69f47af/41598_2024_63457_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e2d/11143240/e1da7fe8f2a0/41598_2024_63457_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e2d/11143240/118721c42b85/41598_2024_63457_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e2d/11143240/683ee3ab13a9/41598_2024_63457_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e2d/11143240/87a243761c0f/41598_2024_63457_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e2d/11143240/616402925d73/41598_2024_63457_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e2d/11143240/320ac69f47af/41598_2024_63457_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e2d/11143240/e1da7fe8f2a0/41598_2024_63457_Fig6_HTML.jpg

相似文献

[1]
NLRC5 promotes endometrial carcinoma progression by regulating NF-κB pathway-mediated mismatch repair gene deficiency.

Sci Rep. 2024-5-30

[2]
NLRC5 promotes cell migration and invasion by activating the PI3K/AKT signaling pathway in endometrial cancer.

J Int Med Res. 2020-5

[3]
PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.

Am J Surg Pathol. 2017-3

[4]
Molecular Modifiers of Hormone Receptor Action: Decreased Androgen Receptor Expression in Mismatch Repair Deficient Endometrial Endometrioid Adenocarcinoma.

Int J Gynecol Pathol. 2019-1

[5]
LC3 and NLRC5 interaction inhibits NLRC5-mediated MHC class I antigen presentation pathway in endometrial cancer.

Cancer Lett. 2022-3-31

[6]
Retained PAX2 expression associated with DNA mismatch repair deficiency in endometrial endometrioid adenocarcinoma.

Histopathology. 2024-11

[7]
CircATXN7 regulates the proliferation and invasion of esophageal cancer cells through miR-4319/NLRC5.

Cell Signal. 2024-10

[8]
Effect of NLRC5 on activation and reversion of hepatic stellate cells by regulating the nuclear factor-κB signaling pathway.

World J Gastroenterol. 2019-6-28

[9]
Discordant prognosis of mismatch repair deficiency in colorectal and endometrial cancer reflects variation in antitumour immune response and immune escape.

J Pathol. 2022-7

[10]
Selective autophagy of NLRC5 promotes immune evasion of endometrial cancer.

Autophagy. 2022-4

引用本文的文献

[1]
Reassessing the Role of Tissue Factor Pathway Inhibitor 2 in Neoplastic and Non-Neoplastic Lesions.

Cancers (Basel). 2025-4-25

[2]
New insights into the structure domain and function of NLR family CARD domain containing 5.

Cell Commun Signal. 2025-1-23

本文引用的文献

[1]
NLRC5 potentiates anti-tumor CD8 T cells responses by activating interferon-β in endometrial cancer.

Transl Oncol. 2023-10

[2]
NLR family CARD domain containing 5 promotes hypoxia-induced cancer progress and carboplatin resistance by activating PI3K/AKT via carcinoembryonic antigen related cell adhesion molecule 1 in non-small cell lung cancer.

Bioengineered. 2022-6

[3]
USP14-mediated NLRC5 upregulation inhibits endothelial cell activation and inflammation in atherosclerosis.

Biochim Biophys Acta Mol Cell Biol Lipids. 2023-5

[4]
The Role of Immunohistochemistry Markers in Endometrial Cancer with Mismatch Repair Deficiency: A Systematic Review.

Cancers (Basel). 2022-8-3

[5]
Inhibition of NLRC5 attenuates the malignant growth and enhances the sensitivity of gastric cancer cells to 5-FU chemotherapy by blocking the carcinogenic effect of YY1.

Exp Ther Med. 2022-7-28

[6]
NLRC5 Might Promote Endometrial Cancer Progression by Inducing PD-L1 Expression.

Technol Cancer Res Treat. 2022

[7]
Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study.

J Clin Oncol. 2022-3-1

[8]
LC3 and NLRC5 interaction inhibits NLRC5-mediated MHC class I antigen presentation pathway in endometrial cancer.

Cancer Lett. 2022-3-31

[9]
NLRC5 attenuates inflammatory response in IL-1β-stimulated human osteoarthritis chondrocytes through the NF-κB signaling pathway.

Aging (Albany NY). 2021-8-26

[10]
NLRC5/CITA expression correlates with efficient response to checkpoint blockade immunotherapy.

Sci Rep. 2021-2-5

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索